Immunomedics Inc. (IMMU) 3.05 $IMMU
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Immunomedics, Inc. (IMMU)
GlobeNewswire - Fri Jun 10, 8:00PM CDT
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Immunomedics, Inc. ("Immunomedics" or the "Company"
(Nasdaq:IMMU) in the United States District Court for the District of New Jersey on behalf of purchasers of Immunomedics common stock between April 20, 2016 through June 2, 2016, inclusive (the "Class Period" , seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act" .
IMMU: 3.05 (-0.08)
Block & Leviton LLP Files Class Action Lawsuit Against Immunomedics, Inc., Alleging Violations Of The Federal Securities Laws
PR Newswire - Fri Jun 10, 7:11PM CDT
Block & Leviton LLP (blockesq.com) announces that it has filed a class action lawsuit against Immunomedics, Inc. ("Immunomedics" or the "Company" (Nasdaq: IMMU) and certain of its officers for violations of the federal securities laws.
IMMU: 3.05 (-0.08)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Immunomedics Inc. (IMMU) and Lead Platintiff Deadline: August 8, 2016
PR Newswire - Fri Jun 10, 11:14AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, notifies investors of class action against of Immunomedics, Inc. ("Immunomedics" or the "Company" (NASDAQGM: IMMU -News). The class action has been filed in the United States District Court, District of New Jersey, on behalf of a class consisting of all persons or entities who purchased Immunomedics common stock between April 20, 2016 and June 2, 2016 inclusive (the "Class Period" .
IMMU: 3.05 (-0.08)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunomedics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 8, 2016 - IMMU
GlobeNewswire - Fri Jun 10, 10:19AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
IMMU: 3.05 (-0.08)
IMMUNOMEDICS, INC. INVESTOR ALERT: Hagens Berman Alerts Immunomedics, Inc. Investors of Investigation into Company's ASCO Rule Violation
BusinessWire - Fri Jun 10, 2:30AM CDT
The following statement is being issued by Hagens Berman Sobol Shapiro LLP:
IMMU: 3.05 (-0.08)
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Immunomedics, Inc. - IMMU
BusinessWire - Thu Jun 09, 6:07PM CDT
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Immunomedics, Inc. securities (NASDAQ:IMMU) from April 20, 2016 through June 2, 2016, both dates inclusive (the "Class Period" . The lawsuit seeks to recover damages for Immunomedics investors under the federal securities laws.
IMMU: 3.05 (-0.08)
Pomerantz Law Firm Announces the Filing of a Class Action Against Immunomedics, Inc. and Certain Officers - IMMU
GlobeNewswire - Thu Jun 09, 5:09PM CDT
Pomerantz LLP announces that a class action lawsuit has been filed against Immunomedics, Inc. ("Immunomedics" or the "Company" (NASDAQ:IMMU) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Immunomedics securities between April 20, 2016 and June 2, 2016 inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
IMMU: 3.05 (-0.08)
Immunomedics to Present at Jefferies 2016 Global Healthcare Conference
GlobeNewswire - Tue Jun 07, 6:00AM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today announced that the Company will present at Jefferies 2016 Global Healthcare Conference at 11:30 a.m. Eastern Time on Friday, June 10, 2016, in New York City. The presentation, which will be posted on the Company's website at www.immunomedics.com, will provide a corporate overview.
IMMU: 3.05 (-0.08)
Immunomedics' Sacituzumab Govitecan (IMMU-132) Demonstrates Efficacy and Safety in Non-Small-Cell Lung Cancer Patients With Multiple Prior Treatments, Including Immuno-Oncology
GlobeNewswire - Mon Jun 06, 2:15PM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today announced that sacituzumab govitecan (IMMU-132), its lead investigational antibody-drug conjugate (ADC), shrank tumors by 30% or more initially in 26% (12/46) of evaluable patients with metastatic non-small-cell lung cancer (NSCLC), with a later confirmed overall objective response rate (ORR) of 13%, in accordance with RECIST 1.1 criteria. For the patients with confirmed responses, the duration of response (DOR) was 9 months.
IMMU: 3.05 (-0.08)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immunomedics Inc. - IMMU
ACCESSWIRE - Mon Jun 06, 11:21AM CDT
NEW YORK, NY / ACCESSWIRE / June 6, 2016 / Pomerantz LLP is investigating claims on behalf of investors of Immunomedics Inc. ("Immunomedics" or the "Company" (NASDAQ: IMMU). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
IMMU: 3.05 (-0.08)
Immunomedics Announces Sacituzumab Govitecan (IMMU-132) is Active in Patients With Previously-Treated Metastatic Small-Cell Lung Cancer
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today reported an overall response rate of 24% (8/33) in assessable patients with metastatic small-cell lung cancer (SCLC) after receiving treatment with sacituzumab govitecan, its lead investigational antibody-drug conjugate (ADC), at the dose level of 8 mg/kg or 10 mg/kg. Three of the eight partial responders (PRs) have been confirmed with a follow-up computed tomography scan, to yield a confirmed response rate of 9%. The remaining five initial responders had progressive disease at the confirmatory scan.
IMMU: 3.05 (-0.08)
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims against Immunomedics Inc. and Advises Investors with Losses to Contact the Firm
BusinessWire - Fri Jun 03, 4:24PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Immunomedics Inc. ("Immunomedics" or the "Company" (Nasdaq: IMMU). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
IMMU: 3.05 (-0.08)
EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against Immunomedics, Inc. - IMMU
BusinessWire - Fri Jun 03, 1:45PM CDT
The Rosen Law Firm, P.A., a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Immunomedics, Inc. (NASDAQ:IMMU) resulting from allegations that Immunomedics may have issued materially misleading business information to the investing public.
IMMU: 3.05 (-0.08)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Immunomedics Inc.
PR Newswire - Fri Jun 03, 12:08PM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Immunomedics, Inc. ("Immunomedics" or the "Company" (NASDAQGM: IMMU -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
IMMU: 3.05 (-0.08)
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immunomedics Inc. - IMMU
PR Newswire - Fri Jun 03, 10:08AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Immunomedics Inc. ("Immunomedics" or the "Company" (NASDAQ: IMMU). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
IMMU: 3.05 (-0.08)
Immunomedics Investigated For Securities Fraud By Block & Leviton After Revelation That Company Misrepresented Data At Important Conference
PR Newswire - Fri Jun 03, 8:22AM CDT
Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Immunomedics Inc. (Nasdaq: IMMU) and its husband-and-wife executives David Goldenberg and Cynthia Sullivan have violated federal securities laws following the news today that the company misrepresented data at an important conference.
IMMU: 3.05 (-0.08)
Immunomedics Provides Update on Triple-Negative Breast Cancer Presentation at ASCO
GlobeNewswire - Fri Jun 03, 8:16AM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today announced that the Company was advised late yesterday that its abstract, "Therapy of refractory/relapsed metastatic triple-negative breast cancer (mTNBC) with an anti-Τrop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results," planned for oral presentation today and selected by the American Society of Clinical Oncology (ASCO) for its Press Briefing, was cancelled because of a complaint that the Company violated the embargo by reporting results presented by its Chairman at a conference in April. It appears the complaint was made by a third party contacting ASCO. No question was raised on the quality of the results.
IMMU: 3.05 (-0.08)
Why These Biotech Stocks Have Been on Investors' Radar? - Juno Therapeutics, Immunomedics, Ultragenyx Pharma, and Intercept Pharma
PR Newswire - Wed May 25, 7:10AM CDT
The Biotech arena may not be in its best shape right now, but this does not mean investors are sidelining stocks in this space. Here are today's ActiveWallSt.com highlights: Juno Therapeutics Inc. (NASDAQ: JUNO), Immunomedics Inc. (NASDAQ: IMMU), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Get the free access these stocks' technical alerts by clicking below:
IMMU: 3.05 (-0.08), RARE: 61.58 (-4.27), ICPT: 150.66 (-3.56), JUNO: 42.98 (-2.55)
Immunomedics to Report Updated Results for Sacituzumab Govitecan (IMMU-132) in Breast and Lung Cancers at Clinical Science Symposia of 2016 ASCO Annual Meeting
GlobeNewswire - Thu May 19, 6:00AM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today announced that the Scientific Program Committee of the American Society of Clinical Oncology (ASCO) has selected two of the Company's abstracts for oral presentation at two Clinical Science Symposium Sessions during their 2016 Annual Meeting, scheduled for June 3-7, 2016 at McCormick Place Convention Center in Chicago, Illinois.
IMMU: 3.05 (-0.08)
Immunomedics reports 3Q loss
Automated Insights - Wed May 04, 4:25PM CDT
MORRIS PLAINS, N.J. (AP) _ Immunomedics Inc. (IMMU) on Wednesday reported a loss of $14 million in its fiscal third quarter.
IMMU: 3.05 (-0.08)
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Immunomedics, Inc. (IMMU)
GlobeNewswire - Fri Jun 10, 8:00PM CDT
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Immunomedics, Inc. ("Immunomedics" or the "Company"
(Nasdaq:IMMU) in the United States District Court for the District of New Jersey on behalf of purchasers of Immunomedics common stock between April 20, 2016 through June 2, 2016, inclusive (the "Class Period" , seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act" . IMMU: 3.05 (-0.08)
Block & Leviton LLP Files Class Action Lawsuit Against Immunomedics, Inc., Alleging Violations Of The Federal Securities Laws
PR Newswire - Fri Jun 10, 7:11PM CDT
Block & Leviton LLP (blockesq.com) announces that it has filed a class action lawsuit against Immunomedics, Inc. ("Immunomedics" or the "Company"
(Nasdaq: IMMU) and certain of its officers for violations of the federal securities laws. IMMU: 3.05 (-0.08)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Immunomedics Inc. (IMMU) and Lead Platintiff Deadline: August 8, 2016
PR Newswire - Fri Jun 10, 11:14AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, notifies investors of class action against of Immunomedics, Inc. ("Immunomedics" or the "Company"
(NASDAQGM: IMMU -News). The class action has been filed in the United States District Court, District of New Jersey, on behalf of a class consisting of all persons or entities who purchased Immunomedics common stock between April 20, 2016 and June 2, 2016 inclusive (the "Class Period" . IMMU: 3.05 (-0.08)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunomedics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 8, 2016 - IMMU
GlobeNewswire - Fri Jun 10, 10:19AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
IMMU: 3.05 (-0.08)
IMMUNOMEDICS, INC. INVESTOR ALERT: Hagens Berman Alerts Immunomedics, Inc. Investors of Investigation into Company's ASCO Rule Violation
BusinessWire - Fri Jun 10, 2:30AM CDT
The following statement is being issued by Hagens Berman Sobol Shapiro LLP:
IMMU: 3.05 (-0.08)
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Immunomedics, Inc. - IMMU
BusinessWire - Thu Jun 09, 6:07PM CDT
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Immunomedics, Inc. securities (NASDAQ:IMMU) from April 20, 2016 through June 2, 2016, both dates inclusive (the "Class Period"
. The lawsuit seeks to recover damages for Immunomedics investors under the federal securities laws. IMMU: 3.05 (-0.08)
Pomerantz Law Firm Announces the Filing of a Class Action Against Immunomedics, Inc. and Certain Officers - IMMU
GlobeNewswire - Thu Jun 09, 5:09PM CDT
Pomerantz LLP announces that a class action lawsuit has been filed against Immunomedics, Inc. ("Immunomedics" or the "Company"
(NASDAQ:IMMU) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Immunomedics securities between April 20, 2016 and June 2, 2016 inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . IMMU: 3.05 (-0.08)
Immunomedics to Present at Jefferies 2016 Global Healthcare Conference
GlobeNewswire - Tue Jun 07, 6:00AM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today announced that the Company will present at Jefferies 2016 Global Healthcare Conference at 11:30 a.m. Eastern Time on Friday, June 10, 2016, in New York City. The presentation, which will be posted on the Company's website at www.immunomedics.com, will provide a corporate overview.
IMMU: 3.05 (-0.08)
Immunomedics' Sacituzumab Govitecan (IMMU-132) Demonstrates Efficacy and Safety in Non-Small-Cell Lung Cancer Patients With Multiple Prior Treatments, Including Immuno-Oncology
GlobeNewswire - Mon Jun 06, 2:15PM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today announced that sacituzumab govitecan (IMMU-132), its lead investigational antibody-drug conjugate (ADC), shrank tumors by 30% or more initially in 26% (12/46) of evaluable patients with metastatic non-small-cell lung cancer (NSCLC), with a later confirmed overall objective response rate (ORR) of 13%, in accordance with RECIST 1.1 criteria. For the patients with confirmed responses, the duration of response (DOR) was 9 months.
IMMU: 3.05 (-0.08)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immunomedics Inc. - IMMU
ACCESSWIRE - Mon Jun 06, 11:21AM CDT
NEW YORK, NY / ACCESSWIRE / June 6, 2016 / Pomerantz LLP is investigating claims on behalf of investors of Immunomedics Inc. ("Immunomedics" or the "Company"
(NASDAQ: IMMU). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. IMMU: 3.05 (-0.08)
Immunomedics Announces Sacituzumab Govitecan (IMMU-132) is Active in Patients With Previously-Treated Metastatic Small-Cell Lung Cancer
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today reported an overall response rate of 24% (8/33) in assessable patients with metastatic small-cell lung cancer (SCLC) after receiving treatment with sacituzumab govitecan, its lead investigational antibody-drug conjugate (ADC), at the dose level of 8 mg/kg or 10 mg/kg. Three of the eight partial responders (PRs) have been confirmed with a follow-up computed tomography scan, to yield a confirmed response rate of 9%. The remaining five initial responders had progressive disease at the confirmatory scan.
IMMU: 3.05 (-0.08)
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims against Immunomedics Inc. and Advises Investors with Losses to Contact the Firm
BusinessWire - Fri Jun 03, 4:24PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Immunomedics Inc. ("Immunomedics" or the "Company"
(Nasdaq: IMMU). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors. IMMU: 3.05 (-0.08)
EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against Immunomedics, Inc. - IMMU
BusinessWire - Fri Jun 03, 1:45PM CDT
The Rosen Law Firm, P.A., a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Immunomedics, Inc. (NASDAQ:IMMU) resulting from allegations that Immunomedics may have issued materially misleading business information to the investing public.
IMMU: 3.05 (-0.08)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Immunomedics Inc.
PR Newswire - Fri Jun 03, 12:08PM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Immunomedics, Inc. ("Immunomedics" or the "Company"
(NASDAQGM: IMMU -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484. IMMU: 3.05 (-0.08)
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immunomedics Inc. - IMMU
PR Newswire - Fri Jun 03, 10:08AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Immunomedics Inc. ("Immunomedics" or the "Company"
(NASDAQ: IMMU). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. IMMU: 3.05 (-0.08)
Immunomedics Investigated For Securities Fraud By Block & Leviton After Revelation That Company Misrepresented Data At Important Conference
PR Newswire - Fri Jun 03, 8:22AM CDT
Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Immunomedics Inc. (Nasdaq: IMMU) and its husband-and-wife executives David Goldenberg and Cynthia Sullivan have violated federal securities laws following the news today that the company misrepresented data at an important conference.
IMMU: 3.05 (-0.08)
Immunomedics Provides Update on Triple-Negative Breast Cancer Presentation at ASCO
GlobeNewswire - Fri Jun 03, 8:16AM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today announced that the Company was advised late yesterday that its abstract, "Therapy of refractory/relapsed metastatic triple-negative breast cancer (mTNBC) with an anti-Τrop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results," planned for oral presentation today and selected by the American Society of Clinical Oncology (ASCO) for its Press Briefing, was cancelled because of a complaint that the Company violated the embargo by reporting results presented by its Chairman at a conference in April. It appears the complaint was made by a third party contacting ASCO. No question was raised on the quality of the results.
IMMU: 3.05 (-0.08)
Why These Biotech Stocks Have Been on Investors' Radar? - Juno Therapeutics, Immunomedics, Ultragenyx Pharma, and Intercept Pharma
PR Newswire - Wed May 25, 7:10AM CDT
The Biotech arena may not be in its best shape right now, but this does not mean investors are sidelining stocks in this space. Here are today's ActiveWallSt.com highlights: Juno Therapeutics Inc. (NASDAQ: JUNO), Immunomedics Inc. (NASDAQ: IMMU), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Get the free access these stocks' technical alerts by clicking below:
IMMU: 3.05 (-0.08), RARE: 61.58 (-4.27), ICPT: 150.66 (-3.56), JUNO: 42.98 (-2.55)
Immunomedics to Report Updated Results for Sacituzumab Govitecan (IMMU-132) in Breast and Lung Cancers at Clinical Science Symposia of 2016 ASCO Annual Meeting
GlobeNewswire - Thu May 19, 6:00AM CDT
Immunomedics, Inc., (Nasdaq:IMMU) today announced that the Scientific Program Committee of the American Society of Clinical Oncology (ASCO) has selected two of the Company's abstracts for oral presentation at two Clinical Science Symposium Sessions during their 2016 Annual Meeting, scheduled for June 3-7, 2016 at McCormick Place Convention Center in Chicago, Illinois.
IMMU: 3.05 (-0.08)
Immunomedics reports 3Q loss
Automated Insights - Wed May 04, 4:25PM CDT
MORRIS PLAINS, N.J. (AP) _ Immunomedics Inc. (IMMU) on Wednesday reported a loss of $14 million in its fiscal third quarter.
IMMU: 3.05 (-0.08)
